Regenesis
Cartilage Regeneration through Electrical Stimulations
Company Overview
Snapshot
Founded in February 2023, Regenesis operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative cartilage regeneration technology.
Business overview
Regenesis is a biomedical startup dedicated to revolutionizing the treatment of cartilage lesions. The company's core technology involves a unique biocompatible structure designed to enhance in situ cartilage regeneration through a minimally invasive procedure. This platform can be adapted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA). Regenesis operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.
Log in to access full profile ›Company Intelligence Q&A
- What is Regenesis's primary focus?
- Regenesis is a biomedical startup focused on cartilage regeneration through electrical stimulations, aiming to treat cartilage lesions with a minimally invasive procedure.
- When was Regenesis founded?
- Regenesis was founded in February 2023.
- What is the core technology behind Regenesis's platform?
- The core technology is based on a unique biocompatible structure designed to be applied directly or indirectly to damaged areas for tissue regeneration.
- What medical conditions does Regenesis's platform address?
- The platform can be adopted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA).
- Does Regenesis hold any patents?
- Yes, Regenesis holds a patent for its technology.